Trilogy Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.18M | Buy |
41,026
+9,777
| +31% | +$1.29M | 0.2% | 86 |
|
|
2026
Q1 | $4.36M | Buy |
31,249
+1,546
| +5% | +$216K | 0.19% | 85 |
|
|
2025
Q4 | $3.65M | Buy |
29,703
+2,204
| +8% | +$268K | 0.16% | 101 |
|
|
2025
Q3 | $3.05M | Sell |
27,499
-48
| -0.2% | -$5.46K | 0.14% | 109 |
|
|
2025
Q2 | $3.05M | Sell |
27,547
-5,700
| -17% | -$607K | 0.15% | 100 |
|
|
2025
Q1 | $3.73M | Sell |
33,247
-4,060
| -11% | -$419K | 0.2% | 77 |
|
|
2024
Q4 | $3.45M | Sell |
37,307
-3,765
| -9% | -$339K | 0.18% | 87 |
|
|
2024
Q3 | $3.44M | Sell |
41,072
-235
| -0.6% | -$17.9K | 0.17% | 92 |
|
|
2024
Q2 | $2.83M | Buy |
41,307
+3,191
| +8% | +$213K | 0.15% | 105 |
|
|
2024
Q1 | $2.79M | Buy |
38,116
+33,202
| +676% | +$2.55M | 0.16% | 112 |
|
|
2023
Q4 | $398K | Sell |
4,914
-458
| -9% | -$35.6K | 0.02% | 190 |
|
|
2023
Q3 | $403K | Sell |
5,372
-419
| -7% | -$32.2K | 0.03% | 177 |
|
|
2023
Q2 | $467K | Buy |
5,791
+742
| +15% | +$59.2K | 0.03% | 176 |
|
|
2023
Q1 | $419K | Sell |
5,049
-23,304
| -82% | -$1.93M | 0.03% | 166 |
|
|
2022
Q4 | $2.43M | Sell |
28,353
-2,602
| -8% | -$206K | 0.17% | 78 |
|
|
2022
Q3 | $1.91M | Buy |
30,955
+3,632
| +13% | +$229K | 0.17% | 62 |
|
|
2022
Q2 | $1.69M | Buy |
27,323
+6,079
| +29% | +$376K | 0.15% | 61 |
|
|
2022
Q1 | $1.26M | Buy |
21,244
+4,284
| +25% | +$274K | 0.09% | 95 |
|
|
2021
Q4 | $1.23M | Buy |
16,960
+757
| +5% | +$52.1K | 0.09% | 81 |
|
|
2021
Q3 | $1.13M | Buy |
16,203
+19
| +0.1% | +$1.33K | 0.09% | 76 |
|
|
2021
Q2 | $1.1M | Buy |
16,184
+6,318
| +64% | +$422K | 0.08% | 78 |
|
|
2021
Q1 | $638K | Buy |
9,866
+741
| +8% | +$47.8K | 0.05% | 116 |
|
|
2020
Q4 | $532K | Buy |
9,125
+46
| +0.5% | +$2.78K | 0.04% | 113 |
|
|
2020
Q3 | $574K | Sell |
9,079
-360
| -4% | -$25K | 0.05% | 91 |
|
|
2020
Q2 | $737K | Buy |
9,439
+1,473
| +18% | +$113K | 0.07% | 71 |
|
|
2020
Q1 | $637K | Buy |
+7,966
| New | +$550K | 0.07% | 67 |
|
|
2019
Q1 | – | Sell |
-3,903
| Closed | -$244K | – | 135 |
|
|
2018
Q4 | $244K | Sell |
3,903
-3,427
| -47% | -$240K | 0.03% | 113 |
|
|
2018
Q3 | $566K | Sell |
7,330
-844
| -10% | -$63.7K | 0.07% | 90 |
|
|
2018
Q2 | $579K | Sell |
8,174
-468
| -5% | -$33K | 0.08% | 74 |
|
|
2018
Q1 | $652K | Buy |
+8,642
| New | +$687K | 0.09% | 69 |
|
Other funds holding GILD
Trilogy Capital's GILD Position: Q2 2026 in Review
Trilogy Capital increased its Gilead Sciences (GILD) stake by 31% in Q2 2026, buying an estimated $1.29M and bringing the position to 41,026 shares worth $5.18M. The position accounts for 0.2% of the portfolio, ranked #86.
Trilogy Capital first reported a position in GILD in Q1 2018 and has held it in 30 quarters since. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Trilogy Capital held 41,026 shares of Gilead Sciences worth $5.18M as of Q2 2026.
- Trilogy Capital bought 9,777 Gilead Sciences shares in Q2 2026, an estimated $1.29M.
- Gilead Sciences made up 0.2% of Trilogy Capital's portfolio in Q2 2026, its #86 holding.
- Trilogy Capital first reported a position in Gilead Sciences in Q1 2018 and has held it in 30 quarters since.
- 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.